ArticleCureus2024
Herpes Zoster and Venous Thromboembolism Following Upadacitinib Treatment for Severe Atopic Dermatitis.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Review of Herpes Zoster Occurrence in Patients With Atopic Dermatitis Treated With JAK Inhibitors.Clinical and translational science · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New medications targeting the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway have been developed through emerging biologics research. However, due to documented adverse effects, including herpes zoster (HZ) and venous thromboembolism (VTE), an extensive patient workup and counseling are necessary before prescribing. We present the case of an 81-year-old patient with severe atopic dermatitis on upadacitinib, a selective JAK1 inhibitor, who developed HZ and VTE, requiring hospitalization. This study emphasizes the need for further research, continuous monitoring, and risk management for HZ and VTE in patients undergoing upadacitinib treatment, especially in high-risk populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.